Circulating Tumor DNA (ctDNA) for Plasma Genotyping and Disease Monitoring in ALK-Positive Anaplastic Lymphoma (ALK+ALCL): A Proof of Concept Study

间变性淋巴瘤激酶 微小残留病 克里唑蒂尼 碱性抑制剂 间变性大细胞淋巴瘤 数字聚合酶链反应 医学 淋巴瘤 内科学 ROS1型 肿瘤科 癌症研究 生物 聚合酶链反应 癌症 基因 白血病 肺癌 遗传学 腺癌 恶性胸腔积液
作者
Damien Vasseur,Samuel Abbou,Ludovic Lacroix,Laurence Lamant,Pata-Merci Noémie,David Sibon,Francesco Facchinetti,Marc Deloger,Floriane Brayé,Véronique Minard‐Colin,Laurence Brugières,Étienne Rouleau,Luc Friboulet,Charlotte Rigaud
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 4375-4375
标识
DOI:10.1182/blood-2023-185808
摘要

Introduction Circulating tumor DNA (ctDNA) detection has not been reported yet in ALK-positive anaplastic large cell lymphoma (ALK+ALCL), a rare aggressive non-Hodgkin lymphoma with a peak incidence in children, adolescents and young adults. In this study, we aimed to evaluate whether ctDNA can be detected, characterized and used to monitor minimal residual disease (MRD) in ALK+ALCL. Patients and Methods Plasma samples were collected from 23 French patients diagnosed with ALK+ALCL between November 2020 and March 2023. Based on cell-free DNA (cfDNA) extracted from plasma, we performed shallow whole genome sequencing (shWGS) and a comprehensive genomic profiling (CGP) of more than 500 genes covered at a median depth of over 3000 unique reads to assess ctDNA content. In this study, we defined samples as positive if they had a tumor fraction over 3%, evaluated by shWGS analysis, or if ALK rearrangements were identified using CGP. Additionally, ALK rearrangement genomic breakpoint were defined by CGP analysis. For each patient, specific digital droplet PCR (ddPCR) assays were designed based on the identified breakpoints to monitor ctDNA content during the ALK+ALCL disease follow-up. Results The median age of patients at the time of diagnosis was 13 years (range: 4-54). Sixteen patients, (69.6%) received at least one ALK tyrosine kinase inhibitor (TKI). A total of 80 plasma samples were collected at various time points from the 23 patients, with a median of 3 samples per patient (range: 1 - 20). Four samples failed for DNA extraction, resulting in 76 samples available for molecular analysis Of the 76 samples, 43 (56.6%) were analyzed using shWGS, 19 (25%) using CGP among which, 14 were analyzed using both techniques. CGP was found to be a more sensitive method for detecting ctDNA in ALK+ALCL compared to shWGS, with 12 out of 14 samples (85.7%) tested positive with CGP, compared to 5 out of 14 samples (35.7%) with shWGS (p<0.01). Of the 19 samples tested with CGP, ALK rearrangement was identified in 14 samples (73.7%), with NPM1:: ALK fusion detected in 11 samples, and ATIC:: ALK, TRAF1:: ALK and EEF1G:: ALK detected in one sample each. The average tumor mutational burden was low, with 5.3 mutations per megabase (mut/Mb) (range: 0-14.5 mut/Mb). No microsatellite instability was detected. Amplification of MDM4 and MYC genes was observed in three patients each. ANKRD26 was the most frequently mutated gene in the study, with four patients affected. LRP1B, epigenetic modifiers such as EP300 and KMT2A, and TP53 were mutated in three patients each. Interestingly, CGP allowed the identification of the ALK:c.3520T>C;p.(Phe1174Leu) mutation in a plasma sample collected during disease progression while the patient was on long lasting crizotinib therapy. Finally, we monitored MRD, based on ctDNA detection in 49 samples from 12 patients using ddPCR assays. Our results were compared with the established gold standard for MRD monitoring in ALK+ALCL, i.e. RT-PCR on circulating cells performed on the same samples. The ddPCR assay showed a 87% sensitivity, 100% specificity, 100% positive predictive value, and 83% negative predictive value. However, four samples had false-negative results due to pre-analytical sampling issues. These samples had been stored at room temperature without undergoing centrifugation for more than 24 hours. Conclusion To date, this study is the first to report on the feasibility and clinical value of ctDNA for the management of ALK+ALCL patients. CGP demonstrated high sensitivity in detecting ctDNA, identifying the genomic breakpoint within the ALK gene and, for the first time in ALK+ALCL, detecting resistance mutations to ALK TKI. Additionally, our unique patient-specific ddPCR approach was proven to be a cost-effective method for MRD monitoring. Altogether, these findings serve as a proof-of-concept for the development of ctDNA techniques in the clinical management of ALK+ALCL.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
Owen应助贲立辉采纳,获得10
2秒前
3秒前
白桦林泪发布了新的文献求助10
3秒前
嘞是举仔完成签到,获得积分10
4秒前
有米饭没完成签到 ,获得积分10
5秒前
Fine发布了新的文献求助10
5秒前
九九九发布了新的文献求助10
5秒前
wish发布了新的文献求助10
7秒前
8秒前
大喵发布了新的文献求助10
8秒前
Aurora完成签到,获得积分10
10秒前
黄彤彤完成签到,获得积分10
11秒前
公冶笑白发布了新的文献求助10
12秒前
九九九完成签到,获得积分10
13秒前
雪儿完成签到 ,获得积分10
13秒前
赵杰完成签到,获得积分10
13秒前
13秒前
14秒前
14秒前
14秒前
15秒前
15秒前
所所应助water采纳,获得10
16秒前
17秒前
充电宝应助白桦林泪采纳,获得10
17秒前
bbh发布了新的文献求助10
18秒前
11完成签到,获得积分20
18秒前
bbh发布了新的文献求助10
18秒前
卡卡罗特发布了新的文献求助10
18秒前
若空行走发布了新的文献求助10
18秒前
19秒前
bbh发布了新的文献求助10
19秒前
bbh发布了新的文献求助10
19秒前
zyyin发布了新的文献求助10
20秒前
21秒前
22秒前
23秒前
123完成签到,获得积分20
23秒前
共享精神应助嘞是举仔采纳,获得10
24秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989797
求助须知:如何正确求助?哪些是违规求助? 3531910
关于积分的说明 11255394
捐赠科研通 3270563
什么是DOI,文献DOI怎么找? 1805008
邀请新用户注册赠送积分活动 882157
科研通“疑难数据库(出版商)”最低求助积分说明 809190